Thermo Fisher Scientific CD20 Monoclonal Antibody (QCH6A7), Brilliant Violet 421, eBioscience

Thermo Fisher Scientific CD20 Monoclonal Antibody (QCH6A7), Brilliant Violet 421, eBioscience

Applications

• Flow Cytometry (Flow)

Tested Dilution: 1.0 µg/test

Product Specifications

Additional Formats

• APC
• Brilliant UV 661
• PE
• PerCP-eFluor 710
• Request custom conjugation available

Product Specific Information

The monoclonal antibody QCH6A7 reacts with mouse CD20, a B cell-specific 32-kDa membrane protein expressed from late pro-B cells through memory B cells. CD20 is involved in intracellular calcium regulation and B cell proliferation. It is not found on hematopoietic stem cells or plasma cells.

CD20 expression begins after CD19 induction and increases during maturation. Unlike other B cell antigens, CD20 is not shed or internalized upon antibody binding. Monoclonal antibodies against CD20 are used to deplete B cells and are effective in B-cell lymphomas and autoimmune diseases such as rheumatoid arthritis and type I diabetes.

Clone QCH6A7 provides improved staining intensity compared to clone AISB12 in flow cytometric assays.

Applications Reported: Flow cytometric analysis
Applications Tested: Tested on mouse splenocytes and bone marrow cells at ≤1.0 µg/test (100 µL final volume).

Brilliant Violet™ 421 (BV421) emits at 423 nm and is suitable for cytometers equipped with a violet (405 nm) laser. Ensure instrument compatibility.

When using multiple polymer dye-conjugated antibodies, use Super Bright Complete Staining Buffer (Product # SB-4401-42) or Brilliant Stain Buffer™ (Product # 00-4409-75) to minimize non-specific interactions.

Excitation: 407 nm
Emission: 423 nm
Laser: Violet Laser

BRILLIANT VIOLET™ is a trademark of Becton, Dickinson and Company, used under license. Powered by Sirigen™.

Target Information

CD20 is a non-glycosylated surface phosphoprotein (33–37 kDa) expressed on mature and malignant B cells, some T lymphocytes, and follicular dendritic cells. It regulates calcium conductance, cell cycle progression, and B-cell proliferation. CD20 remains on the cell surface after antibody binding and serves as a therapeutic target for B-cell depletion.

Diseases associated with CD20 dysfunction include Ms4a1-related common variable immune deficiency.

For Research Use Only. Not for use in diagnostic procedures or resale without authorization.

제품 이미지